Form 4: Jazz Pharmaceuticals Executive Robert Iannone Reports Share Disposal for Tax Obligations
SEC Form 4
Robert Iannone, EVP, Global Head of R&D at Jazz Pharmaceuticals, disposed of shares to cover tax obligations arising from vesting restricted stock units.
Summary
- On March 5, 2024, Robert Iannone, EVP, Global Head of R&D at Jazz Pharmaceuticals, reported a transaction involving ordinary shares.
- Iannone disposed of 4,294 ordinary shares to satisfy tax obligations related to the vesting of previously granted restricted stock units.
- The shares were disposed of at a price of $117.53 per share.
- Following the transaction, Iannone beneficially owns 62,226 ordinary shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine disposal of shares for tax purposes and doesn't inherently indicate a positive or negative outlook.
Industry Context
Executive share transactions are a common occurrence in publicly traded companies. Disposals for tax obligations related to vesting equity are typical and don't necessarily indicate a negative outlook on the company.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine disposal of shares for tax purposes by an executive.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of transaction: Disposal of shares to cover tax obligations. |
| 03/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.